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H ypertension is a common preventable cause of cardiovascu-lar morbidity and mortality and can substantially affect the quality of life and independence of older adults.1 Hyperten-
sion affects 1 in 5 of adults2 worldwide and is generally diagnosed 
and treated in primary health care services. The reported prevalence 
of hypertension among long-term users of glucocorticoids is more 
than 30%3 and it is found in 25%–93% of patients with Cushing syn-
drome.4 The personal and economic impact of hypertension is likely 
to be higher among people with chronic systemic inflammatory dis-
eases, who already have limitations to their activity. These diseases 
are often initially treated with oral glucocorticoids for a minimum of 
3 months,5–11 with disease relapses and flares requiring additional 
glucocorticoid dose escalation in the following years.
It is widely reported that use of oral glucocorticoids is associated 
with an increased risk of hypertension and that this association is 
dose related.3,12 Evidence, however, remains inconsistent, and the 
pathophysiology of glucocorticoid-induced hypertension is 
unclear.12 Three previous population-matched case–control studies 
investigating glucocorticoid-related adverse events among patients 
with psoriasis13 or asthma14,15 reported conflicting results. These 
studies were of relatively small size (< 7000 patients) and had several 
limitations. For example, they excluded a substantial number of 
patients for different reasons (e.g., rheumatic diseases,14 < 30-day 
glucocorticoid exposure in 1 year15), considered only medication 
prescribed by specialists in outpatient or hospital services,13 and did 
not model risk in relation to changing glucocorticoid dose over time 
or reported unadjusted estimates.15 Moreover, none of these studies 
adjusted the estimates of dose–response by disease activity, which 
could also affect the risk of hypertension.
The primary aim of this research was to investigate the effect of 
oral glucocorticoid dose on incident hypertension in patients with 
6 common chronic inflammatory diseases, using linked electronic 
health records in England. The study also examined whether 
adjustment for disease activity over time influenced the estimates.
RESEARCH
Oral glucocorticoids and incidence of 
hypertension in people with chronic inflammatory 
diseases: a population-based cohort study
Teumzghi F. Mebrahtu PhD, Ann W. Morgan PhD, Robert M. West DPhil, Paul M. Stewart MBChB MD,  
Mar Pujades-Rodriguez PhD
n Cite as: CMAJ 2020 MArch 23;192:E295-301. doi: 10.1503/cmaj.191012
ABSTRACT
BACKGROUND: Only a few population-
based studies have examined the asso-
ciation between glucocorticoids and 
hypertension, with inconsistent results. 
We aimed to investigate the effect of 
oral glucocorticoids on incidence of 
hypertension in adults with chronic 
inflammatory diseases.
METHODS: We analyzed electronic health 
records from 389 practices in England 
during 1998–2017 of adults diagnosed 
with any of 6 chronic inflammatory dis-
eases but with no previous diagnosis of 
hypertension. We used glucocorticoid 
 prescription data to construct time- 
variant daily and cumulative variables of 
prednisolone-equivalent dose (cumulated 
from 1 year before the start of follow-up) 
and estimated incidence rates and 
adjusted hazard ratios (HRs) for hyperten-
sion using Cox regression analysis.
RESULTS: Among 71 642 patients in the 
cohort, 24 896 (34.8%) developed hyper-
tension during a median follow-up of 
6.6 years. The incidence rate of hyperten-
sion was 46.7 (95% confidence interval 
[CI] 46.0–47.3) per 1000 person-years. Inci-
dence rates increased with higher cumu-
lative glucocorticoid prednisolone- 
equivalent dose, from 44.4 per 1000 
 person-years in periods of nonuse to 45.3 
per 1000 person-years for periods with 
between > 0.0 and 959.9 mg (HR 1.14, 95% 
CI 1.09–1.19), to 49.3 per 1000  person-years 
for periods with 960–3054.9 mg (HR 1.20, 
95% CI 1.14–1.27), and to 55.6 per 
1000  person-years for periods with 
≥  3055 mg (HR 1.30, 95% CI 1.25–1.35). 
Cumulative effects were seen for the 
6  diseases studied, but dose–response 
effects were not found for daily dose.
INTERPRETATION: Cumulative dose of 
oral glucocorticoids was associated with 
increased incidence of hypertension, 
suggesting that blood pressure should 
be monitored closely in patients rou-
tinely treated with these drugs. Given 
that glucocorticoids are widely pre-
scribed, the associated health burden 
could be high. Trial registration: 
 ClinicalTrials.gov, no.  NCT03760562.
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Methods
Study design
This was a population-based record-linkage cohort study in Eng-
land, using 3 data sources: Clinical Practice Research Datalink 
(CPRD)16 to identify diagnoses, laboratory test results and pre-
scribed medication; Hospital Episode Statistics (www.hscic.gov.uk/
hes) to identify diagnoses recorded during hospital admission; and 
the Office of National Statistics (www.ons.gov.uk/atoz?query = 
mortality&size = 10) to obtain information on date of death and the 
index of multiple deprivation.17 The CPRD is widely used for 
research, and patients are representative of the United Kingdom 
population in terms of age, sex and ethnicity.16,18
Study population
The study included all eligible patients registered in general prac-
tices of the CPRD who had consented to data linkage, between 
Jan. 1, 1998, and Mar. 15, 2017. We included patients when they 
were aged 18 years or older, had been registered in the general prac-
tice for 1 year or more, and had no previous hypertension (Appendix 1, 
Supplemental Figure 1, available at www.cmaj.ca/lookup/suppl/
doi:10.1503/cmaj.191012/-/DC1). All had received a diagnosis of at 
least 1 of 6 chronic inflammatory diseases (inflammatory bowel dis-
ease, systemic lupus erythematosus, polymyalgia rheumatica, giant 
cell arteritis, rheumatoid arthritis and vasculitis) before or during the 
study period (codes are provided in Appendix 1, Supplemental 
Table 1). These diseases are commonly treated with glucocorticoids, 
but dose and treatment duration vary. In the UK, primary care phys-
icians prescribe long-term glucocorticoids for these diseases even if 
guidance on treatment is provided by the specialist.
Ethics approval
The study was approved by the Independent Scientific Advisory 
Committee for Medicines and Healthcare Products Regulatory 
Agency Database Research, reference 16_146.
Definition of hypertension
We defined incident hypertension as the earliest date on which a 
diagnosis of hypertension, or ≥ 3 high systolic or diastolic blood 
pressure measures, was recorded within 12 months during follow-
up. In sensitivity analysis, we also considered the date of first pre-
scribed blood pressure–lowering medication during follow-up. 
Diagnosis codes for hypertension are shown in Appendix 1, Supple-
mentary Table 2. We defined high systolic and diastolic blood pres-
sure values as in current clinical guidelines: ≥  140  mm  Hg and 
≥ 90 mm Hg, respectively.1 We defined history of hypertension at 
study entry (i.e., for exclusion from the study), considering diagno-
sis at any time and high blood pressure measurements or ≥ 1 pre-
scription of blood pressure–lowering medication in the last year.
Definition of oral glucocorticoid exposure
We defined glucocorticoid exposure status using all drug prescrip-
tions for oral glucocorticoids issued in primary care. We extracted 
glucocorticoid doses from the directions given (e.g., once daily), 
product strength (e.g., 5  mg) and prescribed quantity. We con-
verted dosages into prednisolone-equivalent dose to account for 
differences in potency of different types of glucocorticoids.19 See 
Appendix 1, Supplementary Table 3 for conversion rates.
To prevent length- and time-dependent bias,20 we analyzed 
periods covered or not by medication prescription (Appendix 1, 
Supplementary Methods).
We constructed time-variant continuous and categorical vari-
ables of daily dose and cumulative dose (which was cumulated 
from 1 year before the start of follow-up) (Appendix 1). The 
categor ies for daily dose were nonuse, >  0–4.9, 5.0–7.4 and 
≥ 7.5 mg; and for cumulative dose were nonuse, > 0–959.9, 960–3, 
054.9, and ≥ 3055 mg. We based cut-offs for the categorical vari-
ables on previous studies21–23 to facilitate comparability.
Confounders
Our selection of confounders was guided by our clinical, biological 
and epidemiologic understanding. We selected confounding 
variables using DAGitty software.24 This approach for the analysis of 
causal inference in epidemiology determines covariate adjustment 
sets for minimizing confounding bias. Identified minimal sufficient 
adjustment sets are equally valid for causally different but 
statistically equivalent representations of the causal relationship 
examined, making it unnecessary to adjust for other covariates not 
included in that set. Of 10 robust minimal sufficient adjustment sets 
identified for estimating the causal effect of glucocorticoids on 
hypertension (Appendix 1, Supplemental Figure 3), we selected a set 
with age (continuous), index of multiple deprivation (5 categories), 
underlying inflammatory diseases (time-variant), non-oral 
glucocorticoids (binary), cardiovascular disease (binary), chronic 
renal disease stage 3 or 4 (binary) and scleroderma (time-variant).
Statistical analysis
The start date of study follow-up was the earliest date on which all eli-
gibility criteria were met. The end date of the follow-up was the last 
date of data collection in the general practitioner practice, practice 
deregistration or hypertension diagnosis date, whichever came first.
The end date of each drug prescription was not available, and 
we calculated it by adding the duration of days covered by the pre-
scription to the prescription issue date. For each prescription 
recorded, we calculated its duration as the number of tablets pre-
scribed divided by the daily dose. Where data on daily dose or the 
number of tablets prescribed were missing, we used truncated 
multiple imputation (Appendix 1, Supplemental Methods). We 
capped the maximum prescription duration at 90 days, which is the 
maximum recommended duration of prescribed medication in pri-
mary care. We then implemented a clinician-driven algorithm to 
improve the accuracy of imputed dose during tapering periods.
We calculated dose-specific incidence rates as the number of 
hypertension events divided by the total number of person-years at 
risk. We used Cox proportional hazard models to estimate risk of 
hypertension related to glucocorticoid dose. We tested the assump-
tion of proportional hazard by allowing covariates to interact with 
analysis time. Where the assumption was violated, we included 
interaction terms with significant coefficients in the models.
We imputed missing data on daily doses and number of tablets 
prescribed using truncated regression and imputed 50 data sets 
(Appendix 1, Supplemental Methods). Information on outcome and 
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covariates was complete, so no imputation was required. The asso-
ciation between prednisolone-equivalent dose and hypertension 
was nonlinear (p value for departure from linearity was < 0.001). We 
adopted 5% significance levels and 95% confidence intervals (CIs) 
throughout. We performed all analyses in STATA (version 14.1).
In sensitivity analyses, we investigated the effects of disease 
severity on dose-related risks of hypertension through adjustment 
by periods of disease activity and further adjusted estimates for 
hypertension-inducing medication use during follow-up. In addi-
tion, we estimated dose-related risks of hypertension for each 
chronic inflammatory disease and used mixed-effect models to 
account for variation at general practice level.
Results
The study included 71 642 participants from 389 general practices. 
The mean age at study entry was 50.5 years (standard deviation [SD] 
17.4). Sixty-two percent were women and 61 637 (86.0%) were 
white. The most common underlying condition was inflammatory 
bowel disease (25 162; 35.1%), followed by rheumatoid arthritis 
(20 214; 28.2%). Five percent of the patients (n = 3794) had a history 
of cardiovascular disease (Table 1), and 52 711 (73.6%) received 
hypertension-inducing medication during follow-up (Appendix 1, 
Supplemental Table 4).
The average prescribed cumulative dose was 3204 mg 
prednisolone-equivalent dose. Patients with giant cell arteritis had 
the highest values (4410 mg prednisolone-equivalent dose), 
Table 1: Patient baseline characteristics
Characteristic
No. (%) of patients* 
n = 71 642
Sociodemographic information
    Age, yr, mean ± SD 50.5 ± 17.4
    Men 27 252 (38.0)
Ethnicity
    White 61 637 (86.0)
    Black 776 (1.1)
    Asian 2316 (3.2)
Index of multiple deprivation
    1st (least deprived) 13 139 (18.3)
    5th (most deprived) 11 883 (16.6)
Body mass index in kg/m2, mean ± SD 25.7 ± 5.3
Chronic inflammatory disease†
    Giant cell arteritis 3219 (4.5)
    Inflammatory bowel disease 25 162 (35.1)
    Polymyalgia rheumatica 16 385 (22.9)
    Rheumatoid arthritis 20 214 (28.2)
    Systemic lupus erythematosus 3329 (4.7)
    Vasculitis 4473 (6.2)
Comorbidities
    Cardiovascular diseases 3794 (5.3)
    Stage 3 or 4 chronic kidney disease 797 (1.1)
    Scleroderma 57 (0.2)
Non-oral glucocorticoids in last year
    Inhaled 5606 (7.8)
    Nasal 3811 (5.3)
    Intramuscular 297 (0.4)
    Topical 1306 (1.8)
    Rectal 3411 (4.8)
Note: SD = standard deviation.
*Unless stated otherwise.
†Figures include patients with prevalent and incident disease, and some patients 
could have more than 1 disease.
Table 2: Observation time, overall incidence rates and 
time-variant oral glucocorticoids dose–related incidence 
rates of hypertension
Characteristic
Study population 
n = 71 642
Total person-years of follow-up 532 994
Total incident cases, n (%) 24 896 (34.8)
Time at risk per patient, median years (P25–P75) 6.5 (2.7–11.8)
Incidence rates per 1000 person-years (95% CI)
    Overall 46.7 (46.0–47.3)
Daily dose, mg
    Nonuse 46.1 (45.5–46.7)
    > 0–4.9 53.6 (49.5–57.9)
    5.0–7.4 52.8 (48.5–57.5)
    ≥ 7.5 50.7 (47.8–53.8)
Cumulative dose, mg*
    Nonuse 44.4 (43.7–45.4)
    > 0–959.9 45.3 (43.5–47.2)
    960–3054.9 49.3 (46.9–51.8)
    ≥ 3055 55.6 (54.0–57.2)
Note: CI = confidence interval, P25 = 25th centile, P75 = 75th centile.
*Time-variant cumulative dose since 1 year before study entry.
Table 3: Time-variant prescribed prednisolone-equivalent 
dose of oral glucocorticoids and risk of hypertension
Dose variable HR (95% CI)* HR (95% CI)†
Daily dose category, mg
    Nonuse (Ref.) 1 1
    > 0–4.9 0.97 (0.90–1.06) 1.03 (0.95–1.11)
    5.0–7.4 1.02 (0.93–1.11) 1.07 (0.99–1.17)
    ≥ 7.5 1.08 (1.01–1.14) 1.12 (1.06–1.19)
Cumulative dose, mg‡
    Nonuse (Ref.) 1 1
    > 0–959.9 1.14 (1.09–1.19) 1.17 (1.12–1.22)
    960–3054.9 1.20 (1.14–1.27) 1.24 (1.18–1.31)
    ≥ 3055 1.30 (1.25–1.35) 1.36 (1.31–1.41)
Note: CI = confidence interval, HR = hazard ratio, Ref. = reference category.
*Estimates adjusted for baseline age, index of multiple deprivation, non-oral 
glucocorticoid use (inhaled, nasal, intramuscular, intra-articular, topical or rectal), 
comorbidities (cardiovascular disease, chronic kidney disease and scleroderma) and 
type of chronic inflammatory disease.
†Estimates further adjusted for hypertension-inducing medication use during 
follow-up (drugs listed in Appendix 1, Supplemental Table 4).
‡Time-variant cumulative dose since 1 year before study entry.
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followed by patients with polymyalgia rheumatica (4364 mg 
prednisolone-equivalent dose). Overall, 40 648 (56.7%) patients had 
received a diagnosis of the underlying disease treated at study entry, 
while 30 994 (43.0%) had received the diagnosis, on average, 5 years 
before the study entry date (Appendix 1, Supplemental Table 5).
Oral glucocorticoids and hypertension
In more than 532 994 person-years of follow-up, there were 24 896 
(34.8%) incident cases of hypertension, 38 (0.2%) of them recorded as 
diagnoses of secondary hypertension, 18 140 (72.8%) as essential 
hypertension and 6718 (27.0%) ascertained through increases in 
blood pressure measurements (i.e., without recorded diagnosis). 
Median follow-up time was 6.5 years (interquartile range 2.7– 11.8 yr) 
and the incidence rate was 46.7 (95% CI 46.0–47.3) per 1000 person-
years. Incidence rates of hypertension increased with higher cumula-
tive glucocorticoid doses and were higher during periods with pre-
scribed glucocorticoids compared with periods of nonuse (Table 2).
There was a significant increase in hazard ratio (HR) of hyper-
tension for cumulative dose, but not for daily prednisolone-
equivalent dose (Table 3). For example, the rates increased by 
14% (HR 1.14, 95% CI 1.09–1.19), 20% (HR 1.20, 95% CI 1.14–1.27), 
and 30% (HR 1.30, 95% CI 1.25–1.35) when patients received 
between > 0.0 and 959.9 mg, 960 and 3054.9 mg, and ≥ 3055 mg 
cumulative prednisolone-equivalent dose over the follow-up 
period, respectively, compared with nonuse.
Dose–response risk of hypertension by type of chronic 
inflammatory disease
The hazard rate of hypertension increased with higher cumulative 
dose categories of oral glucocorticoids in all disease types except 
Inflammatory bowel disease
< 0–959.9 mg
960–3054.9 mg
≥ 3055 mg
Rheumatoid arthritis
< 0–959.9 mg
960–3054.9 mg
≥ 3055 mg
Polymyalgia rheumatica
< 0–959.9 mg
960–3054.9 mg
≥ 3055 mg
Giant cell arteritis
< 0–959.9 mg
960–3054.9 mg
≥ 3055 mg
Vasculitis
< 0–959.9 mg
960–3054.9 mg
≥ 3055 mg
Systemic lupus erythematosus
< 0–959.9 mg
960–3054.9 mg
≥ 3055 mg
Doses
1.07 (1.00–1.18)
0.93 (0.82–1.05)
1.10 (1.01–1.20)
1.11 (1.03–1.21)
1.16 (1.05–1.29)
1.39 (1.30–1.48)
1.18 (1.08–1.28)
1.17 (1.08–1.26)
1.07 (1.01–1.13)
1.13 (0.96–1.33)
1.28 (1.08–1.53)
1.21 (1.07–1.36)
1.15 (0.97–1.38)
1.32 (1.02–1.70)
1.44 (1.24–1.69)
1.05 (0.83–1.33)
1.17 (0.83–1.65)
1.28 (1.06–1.56)
HR (95% CI)
 0.5 1.0 1.5 2.0
Lower hazard 
of hypertension
Higher hazard 
of hypertension
Hazard ratio
Figure 1:Time-variant cumulative prednisolone-equivalent dose of oral glucocorticoids and the risk of hypertension by type of chronic inflammatory disease. Note: 
estimates adjusted for age, index of multiple deprivation, non-oral glucocorticoids (inhaled, nasal, intramuscular, intra-articular, topical or rectal), comorbidities 
(cardiovascular disease, chronic kidney disease and scleroderma) and time-variant inflammatory chronic disease. CI = confidence interval, HR = hazard ratio.
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inflammatory bowel disease and polymyalgia rheumatica, in 
which the observed HRs were similarly increased for all cumula-
tive dose levels (Figure 1). Evidence of dose–response for hyper-
tension related to prescribed oral daily glucocorticoids was found 
only for vasculitis (HR 1.49, 95% CI 1.17–1.90 for a daily dose 
≥ 7.5 mg; Figure 2). Protective effects were found for polymyalgia 
rheumatica (HR 0.83, 95% CI 0.75–0.92 for a daily dose ≥ 7.5 mg).
Results from sensitivity analyses
In our sensitivity analyses, the estimates of dose–response for 
hypertension were generally similar to the primary analysis, but 
were higher for patients with systemic lupus erythematosus and 
polymyalgia rheumatica, when further adjusted for periods of dis-
ease severity or hypertension-inducing medication, or when 
mixed-effect models were used (Appendix 1, Supplemental Tables 
6–8 and Table 3). Hazard ratios for all cumulative dose levels were 
similar when hypertension was defined considering blood 
 pressure–lowering medication use during follow-up (n = 6468), but 
we found stronger dose–response relationships for daily and 
cumulative dose when these patients were excluded (Table 4).
Interpretation
In this large retrospective cohort study of 71 642 people with 
chronic inflammatory diseases, we found evidence of a dose–
response in hypertension risk with higher cumulative doses of oral 
glucocorticoids. Specifically, when patients reached cumulative 
doses of between ≥ 0.0 and 959.9 mg, 960 and 3054.9 mg and 
≥ 3055 mg prednisolone-equivalent dose during follow-up, the HR 
of hypertension increased by 14%, 20% and 30%, respectively, 
Inflammatory bowel disease
> 0–4.9 mg
5.0–7.4 mg
≥ 7.5 mg
Rheumatoid arthritis
> 0–4.9 mg
5.0–7.4 mg
≥ 7.5 mg
Polymyalgia rheumatica
> 0–4.9 mg
5.0–7.4 mg
≥ 7.5 mg
Giant cell arteritis
> 0–4.9 mg
5.0–7.4 mg
≥ 7.5 mg
Vasculitis
> 0–4.9 mg
5.0–7.4 mg
≥ 7.5 mg
Systemic lupus erythematosus
> 0–4.9 mg
5.0–7.4 mg
≥ 7.5 mg
Doses
0.80 (0.55–1.16)
1.05 (0.79–1.39)
0.94 (0.79–1.12)
1.04 (0.89–1.22)
1.06 (0.93–1.22)
1.07 (0.96–1.19)
0.77 (0.70–0.86)
0.74 (0.64–0.86)
0.83 (0.75–0.92)
0.89 (0.71–1.12)
0.88 (0.64–1.20)
1.01 (0.85–1.20)
0.74 (0.42–1.29)
1.36 (0.91–2.03)
1.49 (1.17–1.90)
0.68 (0.39–1.19)
1.20 (0.80–1.80)
0.97 (0.68–1.38)
HR (95% CI)
0.3 1.0 1.5 2.25
Hazard ratio
Lower hazard 
of hypertension
Higher hazard 
of hypertension
Figure 2: Time-variant daily prednisolone-equivalent dose of oral glucocorticoids and the risk of hypertension by type of chronic inflammatory disease. Note: 
 estimates adjusted for age, index of multiple deprivation, non-oral glucocorticoid use (inhaled, nasal, intramuscular, intra-articular, topical or rectal), comorbid-
ities (cardiovascular disease, chronic kidney disease and scleroderma) and time-variant chronic inflammatory disease. CI = confidence interval, HR = hazard ratio.
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compared with nonuse. Estimates were similar, although higher for 
polymyalgia rheumatica and systemic lupus erythematosus, after 
adjusting for disease severity. In contrast, evidence of dose–
response for prescribed daily dose was found only for vasculitis. 
The difference in effect between current daily and cumulative dose 
could be explained by delays in diagnosis of hypertension (i.e., 
more than 1 in 4 patients with incident hypertension had 3 or more 
measurements of high blood pressure but no recorded diagnosis of 
hypertension) or by a need for a higher dose or longer exposure to 
glucocorticoid therapy for hypertension to be clinically evident. 
This could also explain the inverse dose–response relationship 
found for polymyalgia rheumatica.
Although the link between endogenous glucocorticoid excess 
(Cushing syndrome) and hypertension is known,4,25 findings from 
previous risk association studies in patients with exogenous gluco-
corticoids have been inconsistent.13–15,26 Two matched case–control 
studies found evidence of increased risk of hypertension associated 
with oral glucocorticoids in patients with asthma15 or psoriasis.13 
One study compared unadjusted prevalence of hypertension 
between patients with asthma without prescribed medication in 
the previous 2 years and patients with asthma with prescribed 
medi cation for ≥ 30 days per year (median of 1260 mg prednisolone-
equivalent dose).15 The other study reported higher risk of hyper-
tension in patients with newly diagnosed psoriasis who were pre-
scribed a high cumulative glucocorticoid dose in the previous 
6 months (≥ 45 defined daily dose) compared with nonusers in the 
last year (adjusted odds ratio [OR]  1.87, 95% CI 1.35–2.59).13 In con-
trast, a recent matched case–control study, based on the analysis 
of CPRD data from patients with asthma, reported no evidence of 
increased risk of hypertension for current (within 180 days), recent 
(180–365 days) and past use (> 365 days) of oral glucocorticoids, or 
evidence of dose–response for current daily or cumulative dose 
within the previous 180 days.14 Furthermore, Huscher and col-
leagues26 studied 779 patients with rheumatic arthritis who 
attended outpatient care services in Germany and found higher 
self-reported increases in blood pressure in the previous 6 months 
among patients with a daily dose > 7.5 mg prescribed glucocorti-
coids than among those prescribed lower doses (23.0% v. 18.8%).
Our study has certain strengths. We based the study on the 
analysis of electronic health records from patients registered in 
CPRD family practices. Patients included in CPRD have been 
shown to be representative of the UK population in terms of age, 
sex and ethnicity.16,18 The sample size was large, and errors in 
prescribed medication are minimal given the automatic record-
ing of this information in CPRD. To account for the variation in 
potency of different oral glucocorticoids, doses were standard-
ized (i.e., converted to prednisolone-equivalent dose). We pre-
vented length- and time-dependent bias by analyzing the per-
iods of nonexposure throughout the follow-up period. 
Furthermore, confounding variables were systematically 
selected using statistical tools (directed acyclic graphs) to min-
imize bias due to confounding and overadjustment.
Limitations
The limitations of our study include the lack of recording of the 
end date of glucocorticoid prescriptions and the daily dose dur-
ing tapering periods that we imputed using a combination of sta-
tistical methods and clinician-driven correction algorithms. We 
also underestimated glucocorticoid intake because of the lack of 
information on glucocorticoids administered or prescribed in 
hospital (e.g., high-dose glucocorticoid pulses in patients with 
inflammatory bowel disease, systemic lupus erythematosus or 
vasculitis). This, together with differences in administration pat-
terns or regimens across diseases, might explain the difference in 
the dose–response relationship observed between inflammatory 
bowel disease and other diseases. Furthermore, information on 
oral glucocorticoid prescription was used as a proxy for the 
actual intake of the drugs that assumed optimal adherence.
Table 4: Sensitivity analyses of time-variant prescribed prednisolone-equivalent dose of oral glucocorticoids and the risk 
of hypertension 
Dose variables
Inclusion of patients prescribed blood 
pressure–lowering medication (n = 6468) in 
the definition of incident hypertension,  
HR (95% CI)* 
Exclusion of patients prescribed blood 
pressure–lowering medication (n = 6468) 
from analyses,  
HR (95% CI)*
Daily dose category, mg
    Nonuse (Ref.) 1 1
    > 0–4.9 0.89 (0.82–0.97) 1.51 (1.39–1.63)
    5.0–7.4 1.01 (0.93–1.10) 1.70 (1.56–1.85)
    ≥  7.5 1.17 (1.11–1.24) 1.79 (1.68–1.90)
Overall cumulative dose category, mg
    Nonuse (Ref.) 1 1
    > 0–959.9 1.17 (1.13–1.22) 1.31 (1.25–1.37)
    960–3054.9 1.16 (1.11–1.22) 1.49 (1.41–1.58)
    ≥ 3055 1.20 (1.16–1.25) 1.85 (1.78–1.92)
Note: CI = confidence interval, HR = hazard ratio, Ref. = reference category.
*Models were adjusted for age, index of multiple deprivation, non-oral glucocorticoid use (inhaled, nasal, intramuscular, intra-articular, topical or rectal), comorbidities 
(cardiovascular disease, chronic kidney disease and scleroderma) and type of chronic inflammatory disease.
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We defined hypertension as a binary outcome, based on a 
recorded diagnosis, ≥ 3 high blood pressure values within 1 year or, in 
sensitivity analysis, use of blood pressure–lowering medication. How-
ever, we were unable to examine dose–response effects in relation to 
blood pressure measurements over time and the reversibility of drug 
effects. It was not possible to accurately determine which patients 
with systemic lupus erythematosus or vasculitis had a history of glo-
merulonephritis, which can lead to hypertension, but our analyses 
were adjusted for severe chronic kidney disease (stage 3 or 4). 
Conclusion
The findings of this study indicate that the effect of oral glucocorti-
coid cumulative dose on hypertension is substantial. We suggest 
that blood pressure be closely monitored for early identification 
and management of hypertension in patients with diseases treated 
with long-term glucocorticoids. Given that glucocorticoids are 
widely prescribed,5 the associated health burden could be high.
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